Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Katrina M. Pollock et al.|The Lancet|2020Cited by 2.6k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Gavin Screaton, Wanwisa Dejnirattisai et al.|Cell|2021Cited by 1.2k
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumChang Liu, Mark A. Williams, Helen M. Ginn et al.|Cell|2021Cited by 749
Antibody evasion by the P.1 strain of SARS-CoV-2Wanwisa Dejnirattisai, Gavin Screaton, Daming Zhou et al.|Cell|2021Cited by 661
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie Ewer, Megan Baker, Jordan R. Barrett et al.|Nature Medicine|2020Cited by 643